Diagnosis of HIV and Early Antiretroviral Therapy Initiation Among HIV-1 Infected Infants

CompletedOBSERVATIONAL
Enrollment

1,682

Participants

Timeline

Start Date

May 30, 2019

Primary Completion Date

September 29, 2020

Study Completion Date

September 29, 2020

Conditions
HIV InfectionsHiv
Interventions
DIAGNOSTIC_TEST

Alere Q Testing

Infants of intervention clinics will have heelprick-obtained blood tested by standard of care method (SOC) and Alere™ q HIV-1/2 Detect Test Point of Care testing onsite (i.e. community, household, or facility level). Point-of-care (POC) testing results will be available in 52 minutes. HIV-infected infants, based on the Alere Q test result, will start ART as soon as possible and start routine SOC visits at weeks 2, 4, 8, 12, 16, 20, 24, 36, and 48 post ART-initiation. Study data will be obtained on first 4 routine visits after ART initiation (3 months). Infants will return for results of DBS-based DNA PCR testing. Positive SOC infants remain on ART/study follow-up. Negative POC test/negative SOC infants will attend only routine care visits and continue on HIV prophylaxis per national guidelines. Discordant results require DNA PCR test, with positive results continuing ART, negative results being repeated for confirmation before discontinuation.

Trial Locations (6)

Unknown

George Primary Health Clinic, Lusaka

Kalingalinga Primary Health Clinic, Lusaka

Kamwala Primary Health Clinic, Lusaka

Makeni Primary Health Clinic, Lusaka

Matero Ref Primary Health Clinic, Lusaka

N'gombe Primary Health Clinic, Lusaka

All Listed Sponsors
collaborator

Centre for Infectious Disease Research in Zambia

OTHER

collaborator

Centers for Disease Control and Prevention

FED

lead

University of Alabama at Birmingham

OTHER

NCT03133728 - Diagnosis of HIV and Early Antiretroviral Therapy Initiation Among HIV-1 Infected Infants | Biotech Hunter | Biotech Hunter